Improving BNT162b2 mRNA Vaccine Tolerability without Efficacy Loss by Pidotimod Supplementation
Mediterr J Hematol Infect Dis
.
2022 Mar 1;14(1):e2022023.
doi: 10.4084/MJHID.2022.023.
eCollection 2022.
Authors
Claudio Ucciferri
1
2
,
Jacopo Vecchiet
1
,
Antonio Auricchio
1
,
Katia Falasca
1
Affiliations
1
Clinic of Infectious Diseases - Department of Medicine and Science of Aging, University "G. d'Annunzio" Chieti-Pescara- Italy.
2
Department of Medicine and Health Sciences, University of Molise - Campobasso - Italy.
PMID:
35444768
PMCID:
PMC8992614
DOI:
10.4084/MJHID.2022.023
No abstract available
Keywords:
Adverse events; Covid-19; Immunostimulatory; Pfizer-Biotech; SARS COV2; Safety.